menu
    • menu
    [{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Biosciences \/ Casdin Capital"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Xcell Biosciences \/ Xcell Biosciences"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"Xcell Biosciences \/ ElevateBio"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"TCR-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Xcell Biosciences \/ Xcell Biosciences"},{"orgOrder":0,"company":"Xcell Biosciences","sponsor":"AmplifyBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Expanded Collaboration","leadProduct":"TCR-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Xcell Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Xcell Biosciences \/ AmplifyBio","highestDevelopmentStatusID":"14","companyTruncated":"Xcell Biosciences \/ AmplifyBio"}]

    Find Clinical Drug Pipeline Developments & Deals by Xcell Biosciences

    Menu

    Xcell Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : AmplifyBio

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Xcell Biosciences Expands AmplifyBio Partnership For Cell and Gene Therapies

                            Details : The collaboration aims to identify key elements for successful manufacture of TCR therapies. Experiments have progressed from in vitro to in vivo, to target human papillomavirus-positive tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : AmplifyBio

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : AmplifyBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AmplifyBio And Xcell Partner To Manufacture TCR-T Cell Therapy

                            Details : The partnership aims to focus on TCR therapy and work through process development, preclinical analysis, and first-in-human trials using Xcellbio’s AVATAR Foundry platform for solid tumors.

                            Brand Name : TCR-based Therapy

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 20, 2024

                            Lead Product(s) : TCR-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : AmplifyBio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : ElevateBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Xcell Collaborates with ElevateBio to Advance C&G Therapies Technology Development

                            Details : The collaboration aims to explore novel approaches to improve therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR incubator system for cell therapy research and development.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 11, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : ElevateBio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Labcorp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Labcorp Enhances Cell and Gene Therapy Development Support Through Collaboration With Xcell Biosciences

                            Details : Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system ...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 19, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Labcorp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Xcell Biosciences

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Casdin Capital

                            Deal Size : $27.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Xcellbio Announces $27.5 Million Series B Financing

                            Details : Proceeds will support the company’s continued growth as a pioneer in built-to-purpose technology platforms for the development and manufacturing of cell and gene-based therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 19, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Casdin Capital

                            Deal Size : $27.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth